SCHEMBL4389841

SCHEMBL4389841

Cc1cc(O)cc(=O)n1-c1cc(CO)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
LMNA P02545 2/20 0.35
NOTUM Q6P988 1/20 0.34
APLNR P35414 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PTGER1 P34995 1/20 0.32
MAPK14 Q16539 2/20 0.32
TYR P14679 1/20 0.32
P2RX7 Q99572 1/20 0.32
BCAT2 O15382 1/20 0.32
BCAT1 P54687 1/20 0.32
IDH1 O75874 1/20 0.31
S1PR4 O95977 1/20 0.31
SCD O00767 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467294 0.86 POLB (0.41) POLBLMNANOTUMAPLNRNPC1
SCHEMBL4381315 0.83 POLB (0.40) POLBLMNANOTUMAPLNRNPC1
SCHEMBL4377892 0.77 MAPK14 (0.47) PTGER1MAPK14
SCHEMBL4373994 0.74 POLB (0.41) POLBLMNANOTUMAPLNRMAPT
SCHEMBL4376341 0.70 MAPK14 (0.42) POLBLMNANOTUMAPLNRNPC1
SCHEMBL25309483 0.69 POLB (0.36) POLBMAPK14
SCHEMBL4380059 0.69 CYP1A2 (0.49) LMNANOTUMNPC1MAPTRAB9A
SCHEMBL4380038 0.69 MAPK14 (0.49) MAPK14
SCHEMBL13610554 0.66 HSP90AB1 (0.47) POLBCYP4F2CYP4A11LMNANPC1
SCHEMBL16332319 0.66 NOTUM (0.54) POLBNOTUMAPLNRMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 POLB 1610/4885CYP4F2 1230/4885CYP4A11 1079/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 POLB 1676/4885CYP4F2 816/4885CYP4A11 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.